|
1
|
Hu Z, Tan H, Zhang Y, Qi T, Li Y, Li N, Zhou Z, Wang Y, Wang H, Zhang H, Wang Q. Irisflorentin improves functional recovery after spinal cord injury by protecting the blood-spinal cord barrier and promoting axonal growth. Exp Neurol 2024; 379:114886. [PMID: 38996862 DOI: 10.1016/j.expneurol.2024.114886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 06/29/2024] [Accepted: 07/09/2024] [Indexed: 07/14/2024]
Abstract
Spinal cord injury (SCI) induces the disruption of the blood-spinal cord barrier (BSCB) and the failure of axonal growth. SCI activates a complex series of responses, including cell apoptosis and endoplasmic reticulum (ER) stress. Pericytes play a critical role in maintaining BSCB integrity and facilitating tissue growth and repair. However, the roles of pericytes in SCI and the potential mechanisms underlying the improvements in functional recovery in SCI remain unclear. Recent evidence indicates that irisflorentin exerts neuroprotective effects against Parkinson's disease; however, whether it has potential protective roles in SCI or not is still unknown. In this study, we found that the administration of irisflorentin significantly inhibited pericyte apoptosis, protected BSCB integrity, promoted axonal growth, and ultimately improved locomotion recovery in a rat model of SCI. In vitro, we found that the positive effects of irisflorentin on axonal growth were likely to be mediated by regulating the crosstalk between pericytes and neurons. Furthermore, irisflorentin effectively ameliorated ER stress caused by incubation with thapsigargin (TG) in pericytes. Meanwhile, the protective effect of irisflorentin on BSCB disruption is strongly related to the reduction of pericyte apoptosis via inhibition of ER stress. Collectively, our findings demonstrate that irisflorentin is beneficial for functional recovery after SCI and that pericytes are a valid target of interest for future SCI therapies.
Collapse
Affiliation(s)
- Zhenxin Hu
- Department of Orthopedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325088, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Huixin Tan
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Yu Zhang
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Tengfei Qi
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Yijun Li
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China
| | - Na Li
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Ziheng Zhou
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Yining Wang
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Haoli Wang
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China
| | - Hongyu Zhang
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China.
| | - Qingqing Wang
- Department of Orthopedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325088, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315302, China.
| |
Collapse
|